NASDAQ:NMTR

9 Meters Biopharma Stock Forecast, Price & News

$1.32

0.00 (0.00 %)

(As of 01/15/2021 08:00 PM ET)

Add

Compare

Today's Range

$1.24

Now: $1.32▼

$1.32

50-Day Range

$0.72

MA: $0.99▼

$1.42

52-Week Range

$0.44

Now: $1.32▼

$1.77

Volume145,531 shs

Average Volume23.97 million shs

Market Capitalization$198.43 million

P/E RatioN/A

Dividend YieldN/A

Beta0.11

9 Meters Biopharma, Inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 agonist that is in a Phase 2 clinical trial for SBS; and Larazotide, a Phase 3-stage therapeutic in development for celiac disease. The company also develops NM-003, a proprietary long-acting GLP-2 agonist; and NM-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 Meters Biopharma, Inc. is based in Raleigh, North Carolina.

Overall MarketRank^™

1.38 out of 5 stars

3.5 Analyst's Opinion

Consensus Rating
9 Meters Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, 9 Meters Biopharma has a forecasted upside of 278.8% from its current price of $1.32.
Amount of Analyst Coverage
9 Meters Biopharma has only been the subject of 2 research reports in the past 90 days.

3.4 Community Rank

Outperform Votes
9 Meters Biopharma has received 11 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
9 Meters Biopharma has received 5 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
9 Meters Biopharma has received 68.75% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about 9 Meters Biopharma and other stocks. Vote “Outperform” if you believe NMTR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NMTR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
9 Meters Biopharma does not currently pay a dividend.
Dividend Growth
9 Meters Biopharma does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 9 Meters Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 26.70% of the stock of 9 Meters Biopharma is held by insiders.
Percentage Held by Institutions
Only 19.87% of the stock of 9 Meters Biopharma is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for 9 Meters Biopharma are expected to decrease in the coming year, from $0.10 to ($0.05) per share.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:NMTR

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.9meters.com

Phone919-275-1933

Employees8

Debt

Debt-to-Equity RatioN/A

Current Ratio1.35

Quick Ratio1.35

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.27) per share

Price / Book-4.89

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-27,050,000.00

Net MarginsN/A

Return on EquityN/A

Return on Assets-258.66%

Miscellaneous

Outstanding Shares150,325,000

Market Cap$198.43 million

Next Earnings Date2/8/2021 (Estimated)

OptionableOptionable

$1.32

0.00 (0.00 %)

(As of 01/15/2021 08:00 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive NMTR News and Ratings via Email

Sign-up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.

9 Meters Biopharma (NASDAQ:NMTR) Frequently Asked Questions

Is 9 Meters Biopharma a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" 9 Meters Biopharma stock.
View analyst ratings for 9 Meters Biopharma or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than 9 Meters Biopharma?

Wall Street analysts have given 9 Meters Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but 9 Meters Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is 9 Meters Biopharma's next earnings date?

9 Meters Biopharma is scheduled to release its next quarterly earnings announcement on Monday, February 8th 2021.
View our earnings forecast for 9 Meters Biopharma.

How were 9 Meters Biopharma's earnings last quarter?

9 Meters Biopharma, Inc. (NASDAQ:NMTR) posted its earnings results on Saturday, November, 14th. The company reported ($0.06) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.06).
View 9 Meters Biopharma's earnings history.

What price target have analysts set for NMTR?

5 brokers have issued 12-month price objectives for 9 Meters Biopharma's shares. Their forecasts range from $5.00 to $5.00. On average, they expect 9 Meters Biopharma's stock price to reach $5.00 in the next year. This suggests a possible upside of 278.8% from the stock's current price.
View analysts' price targets for 9 Meters Biopharma or view Wall Street analyst' top-rated stocks.

Who are some of 9 Meters Biopharma's key competitors?

Some companies that are related to 9 Meters Biopharma include ZIOPHARM Oncology (ZIOP), Vanda Pharmaceuticals (VNDA), Esperion Therapeutics (ESPR), G1 Therapeutics (GTHX), Kadmon (KDMN), MannKind (MNKD), Zafgen (ZFGN), Calliditas Therapeutics AB (publ) (CALT), AnaptysBio (ANAB), Foghorn Therapeutics (FHTX), Albireo Pharma (ALBO), Emisphere Technologies (EMIS), Eagle Pharmaceuticals (EGRX), Inventiva (IVA) and Merus (MRUS).
View all of NMTR's competitors.

What other stocks do shareholders of 9 Meters Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 9 Meters Biopharma investors own include Acasti Pharma (ACST), Miragen Therapeutics (MGEN), Bionano Genomics (BNGO), Evofem Biosciences (EVFM), Outlook Therapeutics (OTLK), Tonix Pharmaceuticals (TNXP), Alibaba Group (BABA), Cellectar Biosciences (CLRB), Pfizer (PFE) and Soleno Therapeutics (SLNO).

Who are 9 Meters Biopharma's key executives?

9 Meters Biopharma's management team includes the following people:

Dr. Patrick H. Griffin, Chief Medical Officer (Age 65, Pay $513.12k)
Mr. John Temperato, Pres, CEO & Director (Age 55)
Mr. Edward J. Sitar CPA, CPA, Chief Financial Officer (Age 57)
Mr. Sireesh Appajosyula Pharm.D., Sr. VP of Corp. Devel. & Operations
Jerry Gardner, Head of Clinical Strategy
Dr. Nir Barak, Sr. VP of Scientific Affairs
Dr. Peter H. R. Green M.D., Clinical & Scientific Advisor and Consultant
Mr. Joseph A. Murray, Clinical & Scientific Advisor and Consultant
Dr. Ciaran P. Kelly M.D., Clinical & Scientific Advisor and Consultant
Dr. Elena Verdu M.D., Ph.D., Clinical & Scientific Advisor and Consultant

What is 9 Meters Biopharma's stock symbol?

9 Meters Biopharma trades on the NASDAQ under the ticker symbol "NMTR."

How do I buy shares of 9 Meters Biopharma?

Shares of NMTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is 9 Meters Biopharma's stock price today?

One share of NMTR stock can currently be purchased for approximately $1.32.

How big of a company is 9 Meters Biopharma?

9 Meters Biopharma has a market capitalization of $198.43 million. 9 Meters Biopharma employs 8 workers across the globe.

What is 9 Meters Biopharma's official website?

The official website for 9 Meters Biopharma is www.9meters.com.

How can I contact 9 Meters Biopharma?

9 Meters Biopharma's mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here